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Equine arteritis virus (EAV) is an enveloped plus-strand RNA virus of the family Arteriviridae (order Nidovi-
rales) that causes respiratory and reproductive disease in equids. Protective, virus-neutralizing antibodies
(VNAb) elicited by infection are directed predominantly against an immunodominant region in the membrane-
proximal domain of the viral envelope glycoprotein GL, allowing recently the establishment of a sensitive
peptide enzyme-linked immunosorbent assay (ELISA) based on this particular domain (J. Nugent et al.,
J. Virol. Methods 90:167-183, 2000). By using an infectious cDNA we have now generated, in the controlled
background of a nonvirulent virus, a mutant EAV from which this immunodominant domain was deleted. This
virus, EAV-GL, replicated to normal titers in culture cells, although at a slower rate than wild-type EAV, and
caused an asymptomatic infection in ponies. The antibodies induced neutralized the mutant virus efficiently in
vitro but reacted poorly to wild-type EAV strains. Nevertheless, when inoculated subsequently with virulent
EAV, the immunized animals, in contrast to nonvaccinated controls, were fully protected against disease;
replication of the challenge virus occurred briefly at low though detectable levels. The levels of protection
achieved suggest that an immune effector mechanism other than VNAb plays an important role in protection
against infection. As expected, infection with EAV-GL did not induce a measurable response in our GL-
peptide ELISA while the challenge infection of the animals clearly did. EAV-GL or similar mutants are
therefore attractive marker vaccine candidates, enabling serological discrimination between vaccinated and
wild-type virus-infected animals.
Equine arteritis virus (EAV), a plus-strand RNA virus of the
family Arteriviridae (order Nidovirales), is a worldwide patho-
gen for horses and donkeys. The virus was first isolated from
lung tissue of fetuses aborted during an outbreak in Ohio in
1953 (25, 27) and became the prototype arterivirus; it was
joined later by the lactate dehydrogenase-elevating virus of
mice, simian hemorrhagic fever virus, and porcine reproduc-
tive and respiratory syndrome virus. Though the virus infects
cells from quite a variety of origins in vitro, its host range in
nature is narrowly restricted to equids (17, 19, 36, 52, 54).
In the horse clinical signs of infection vary widely and appear
to depend on the particular strain and dose of the virus, the age
and physical condition of the animal, and possibly also the
route of infection (58, 60). While epidemiological studies in-
dicate that natural infections often occur asymptomatically (16,
46, 61), affected animals may develop moderate-to-severe
symptoms as well. Lethal infections of horses with EAV have
been reported only under experimental conditions (12, 29).
While infected horses usually recover after cessation of vire-
mia, foal death as a result of rapidly progressive bronchoint-
erstitial pneumonia and intestinal necrosis can occur in young
and adolescent pregnant mares. In mares EAV infection does
not seem to affect fertility. Stallions may, however, temporarily
exhibit fertility problems due to a reduced production of mor-
phologically normal sperm cells during the first months after
infection (48).
Transmission of EAV occurs via the respiratory route
through direct contact with infectious aerosolized nasopharyn-
geal secretions from acutely infected horses or other secretions
such as urine; feces and vaginal fluids; and fetal, placental, and
amniotic materials aborted by mares as a result of EAV infec-
tion (60). In addition, infected stallions play an important role
in the epidemiology of the infection as the virus can be trans-
mitted very efficiently by the venereal route. Acutely infected
stallions usually secrete virus with their semen. Moreover, a
proportion of infected stallions ranging from 30 to 50%, de-
pending on horse breed, become persistently infected, excret-
ing the virus in their semen for months or years.
EAV is an enveloped virus. The 12.7-kb RNA genome is
packaged by the nucleocapsid protein (N) into an isometric
nucleocapsid (38, 74) that is in turn surrounded by a lipid
membrane. This envelope contains six proteins. The predom-
inant ones are the GL and M proteins (21), two apparently
triple spanning membrane proteins, the former one of which is
N glycosylated. These proteins occur as disulfide-linked dimers
(23). The remaining four are a small unglycosylated (E) pro-
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tein (55) and three minor glycoproteins (GP2b, GP3, and GP4)
(21, 71), which occur in a heterotrimeric complex (70).
Infection of horses by EAV induces antibodies mainly
against the three major viral structural proteins (N, M, and
GL). This humoral immune response is presently considered to
be the most important factor mediating the recovery of animals
from EAV infection as well as providing the long-lasting im-
munity that protects the animals from future EAV-related
disease, though rarely from reinfection. Indeed, virus-neutral-
izing antibodies (VNAb) start to appear 1 to 2 weeks after
primary infection, and their appearance usually coincides with
the clearance of virus from the circulation (30, 42). Accord-
ingly, passive transfer of colostrum antibodies from immune
mares to foals was found to moderate or prevent EAV disease
(45). Inactivated virus preparations, even when administered
in nonadjuvanted form, have been demonstrated to elicit high
levels of VNAb after repeated application and to provide pro-
tection against disease upon experimental EAV infection (13,
31–34).
The VNAb mapped so far are all directed against the GL
protein (7–9, 15, 18, 35, 67, 68) or, more specifically, against
the ectodomain thereof (7, 8, 18, 35). Although four different
neutralization sites within this approximately 115-residue do-
main (including the signal peptide) have been distinguished,
the vast majority of neutralizing monoclonal antibodies
(MAbs) map to the membrane-proximal region (residues 67 to
106, which includes two of the neutralization sites), and this is
clearly the immunodominant part of the protein (7, 8, 11, 35,
56, 57, 73). Consistently, peptides representing the entire GL
ectodomain or parts of its immunodominant region induced
VNAb (7, 14, 15), while a recombinant protein containing the
complete ectodomain (residues 18 to 122) conferred protec-
tion in ponies against experimental infection (14). Surprisingly,
expression of the GL protein by using an alphavirus vector
induced antibodies against the protein in mice (6) and horses
(5), but these were not virus neutralizing or protective against
EAV infection. Only when the M protein was additionally
coexpressed were these antiviral effects observed.
The present study describes the generation of a EAV dele-
tion mutant, denoted EAV-GL, which lacks amino acids (aa)
66 to 112 of the putative ectodomain of the EAV GL protein.
The virus’s replication features in vitro and its biological prop-
erties in vivo, including its immunogenicity, were studied to
explore the potential for this approach to generate a marker
vaccine against EAV infection. The modification introduced
was based on the fact that this region is immunodominant, and
deletion of the corresponding region was found in a neutral-
ization escape mutant which retained its capacity to infect
RK-13 cells (8). It is also known that the entire GL ectodomain
of EAV may be replaced by the corresponding domains from
other arteriviruses and still retain viability (24). Furthermore,
the peptide antigen GL-OVA (aa 81 to 106), which forms the
basis of an already-developed diagnostic enzyme-linked immu-
nosorbent assay (ELISA) (49), is contained within the deleted
sequence, theoretically permitting the serological discrimina-
tion between vaccinated and infected animals. We further
wished to test whether removal of the immunodominant region
of GL would affect the capacity of the deletion mutant virus to
induce VNAb and, if so, whether the resulting immune re-
sponse would protect against challenge EAV infection.
MATERIALS AND METHODS
Cells and viruses. Baby hamster kidney cells (BHK-21 C13; American Type
Culture Collection) were cultured in Glasgow minimal essential medium
(GMEM; GIBCO BRL Life Technologies) supplemented with 10% heat-inac-
tivated fetal bovine serum (FBS), 100 IU of penicillin per ml, and 100 g of
streptomycin per ml (GMEM–10% FBS). Primary equine embryonic lung cells
(EELs; fibroblastoid) were obtained from an established in-house cell line pre-
pared from an aborted fetus. This cell line was tested and found to be free of
mycoplasma or equine viruses. The cells were maintained in Eagle minimum
essential medium with Earle’s salts (EMEM) (Sigma; M2279) supplemented
with 100 IU of penicillin per ml, 10 g of streptomycin per ml, nonessential
amino acids, L-glutamine to a final concentration of 2 mM, and 10% heat-
inactivated FBS (EMEM–10% FBS). For the in vitro studies, concentrated
stocks of the Utrecht derivative of the Bucyrus strain of EAV were prepared as
described earlier (21), except that the virus was finally suspended in GMEM–
10% FBS. The EAV LP3A virus stock, a single-passage derivative in EEL cells
of LP3A (14), was used for challenge infection of ponies as well as for serological
testing together with the CVL Bucyrus EAV strain (28). These two viruses differ
at some positions in their open reading frame 5 (ORF5) genes but show a high
degree of antigenic cross-reactivity (14).
Antibodies. To generate an antiserum directed against the carboxy terminus of
the EAV GL protein (GLC), the protein endodomain was synthesized in Esch-
erichia coli as a fusion protein containing the glutathione S-transferase protein of
Schistosoma japonicum at the amino terminus. To this end, the relevant part of
EAV ORF5 (20) was amplified from cDNA clone PB106 by PCR using the
primers 750 and 439 (Table 1). Both primers contain a 5 extension introducing
a BamHI restriction enzyme recognition site. The PCR product was digested
with BamHI and ligated into a BamHI-digested pGEX-3X vector (Amersham
Pharmacia Biotech), yielding pAVFP55. The fusion protein was then expressed
in PC2495 cells (Phabagen) by standard procedures. The bacteria were subse-
quently pelleted by centrifugation for 15 min at 5,500 rpm and 4°C in a JA10
rotor (Beckman). The cell pellet was resuspended in 50 ml of ice-cold 50 mM
TABLE 1. Oligonucleotides
Name (polarity) Sequence (5–3)b Positiona Use
A2 () TAAGCGTAGCATAGGGTAG 11557–11575 RT-PCR
A3 () CCGCTGTAAATGCCATAG 11610–11627 RT-PCR
439 () CGGGATCCACCTAAAAATCCCGTCACCAC 11923–11943 Production of GL
C
480 () CGGGATCCAACACAACTATGCCG 11493–11511 Sequencing
750 () CGGGATCCTCCGCCAATTACTGTGGTT 11684–11705 Production of GL
C
JV1 () TTACGACTGGTACGTTGGG 11120–11138 RT-PCR
JV2 () GATACTCACCTAAAATCCCG 11930–11949 RT-PCR
983 () GAGAATTCACGGCCATACCAACAGGTTTTACTGGCGGAAC 11315–11340  11482–11493 Generation of EAV-GL
984 () CTTGCGTGCAAGTGGTTG 10628–10637 Generation of EAV-GL
and RT-PCR
a Nucleotide sequence of the Utrecht variant of the EAV CVL Bucyrus strain.
b The 5 extensions used to introduce BamHI enzyme recognition sites are in boldface.
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Tris-HCl (pH 8.0)–2 mM EDTA–100 g of lysozyme per ml, followed by an
incubation for 20 min at 30°C. The suspension was then sonicated three times for
10 s with the pulse control set at 10 at 4°C with a Sonifier B-10 cell disruptor
(Branson Sonic Power Company). After centrifugation for 15 min at 10,000 rpm
and 4°C in a JA20 rotor (Beckman), the pellet was washed with demineralized
water, with 50 mM Tris-HCl (pH 8.0)–5 mM EDTA–1 M urea, and then with 50
mM Tris-HCl (pH 8.0)–5 mM EDTA–2 M urea. After a final wash with demin-
eralized water and another round of centrifugation, the pellet was resuspended
in 5 ml of Laemmli sample buffer (40) containing 50 mM dithiothreitol. Subse-
quently, the sample was loaded on a preparative sodium dodecyl sulfate (SDS)–
12.5% polyacrylamide gel. After electrophoresis, the gel was stained by incuba-
tion with 0.2 M imidazole–0.1% SDS and then with 0.2 M ZnSO4 (37). The part
of the gel containing the fusion protein was excised and cut up. Next, the protein
present in these gel fragments was eluted either passively by incubation overnight
in phosphate-buffered saline at room temperature or by electroelution with a
homemade device. The protein eluates were pooled and used to immunize a New
Zealand White rabbit essentially as described previously (71).
The production and characterization of the rabbit antipeptide sera SP25,
raised against aa 75 through 95 of the EAV GL protein, and SP06, directed
against the carboxy terminus of the EAV M protein, have been documented
elsewhere (21, 23). The EAV GL-specific murine MAbs 74D(B) and 93B were
generated by Glaser et al. (35).
Construction of EAV-GL. DNA techniques were performed essentially as
described by Sambrook et al. (53). To construct pEANGL, a PCR product was
synthesized with the oligonucleotides 983 and 984 and pEAN515 as the DNA
template. The plasmid pEAN515 is a derivative of EAV infectious cDNA clone
pEAV030-BglII KO (22, 63) in which the cryptic transcription termination signal
at position 8941 to 8956 was removed by site-directed mutagenesis and an MscI
site was simultaneously created (mutations: A8941C, T8945A, C8946G, T8947C,
T8950C, and G8956C). The resulting PCR fragment (724 nucleotides) was
treated with BglII and EcoRI, and the 638-bp digestion product was cloned into
BglII- and EcoRI-digested pEAN515 and sequenced. EAV RNA was transcribed
in vitro from pEANGL and from pEAN515, and parallel cultures of BHK-21
C13 cells were transfected with the synthetic RNAs by electroporation essentially
as described by de Vries et al. (22). Infections and mock infections of BHK-21
cells with wild-type or mutant EAV at a high multiplicity of infection (MOI) have
also been previously reported (71).
Reverse transcription-PCR (RT-PCR) and sequencing. Viral RNA was puri-
fied from supernatants of infected cells and reverse transcribed and PCRs were
performed all by using standard procedures. The primers used in these experi-
ments are listed in Table 1.
Preparation of radiolabeled virions. Subconfluent monolayers of BHK-21 C13
cells were infected with EAV at an MOI of 10. At 6 h postinfection (p.i.) the
medium was removed, and the cells were washed with prewarmed starvation
medium and incubated in 800 l of the same medium. When indicated (see Fig.
4B) 1 mM 1-deoxymannojirimycin (DMJ; Boehringer Mannheim) was added to
the starvation mixture. After a 30-min incubation at 39°C, 80 Ci of Redivue
Pro-mix cell labeling mixture (Amersham Pharmacia Biotech.) was added and
the cells were further incubated at 39°C. At 12 h p.i. the medium was harvested
and cleared by centrifugation for 10 min at 4,000 rpm in an Eppendorf centri-
fuge. The supernatant was then mixed with 1/4 volume of 5 lysis buffer (100
mM Tris-HCl [pH 7.6]–150 mM NaCl–5% Nonidet P-40–2.5% sodium deoxy-
cholate–0.5% SDS containing 5 g each of aprotinin, leupeptin, and pepstatin A
per ml) supplemented with 100 mM N-ethylmaleimide (NEM). The lysate was
cleared and supplemented with EDTA (final concentration, 5 mM).
Characterization of EAV-GL by neutralization test. Portions of EAV stock
(100 tissue culture infective doses [TCID50]) diluted in GMEM were mixed in
parallel in 96-well microtiter plates with 6.25 l of different horse sera or a
similar volume of culture supernatant of hybridoma cells producing MAb 93B or
74D(B) or a similar volume of the rabbit serum SP25. The plates were then
incubated for 1 h at room temperature, after which 6.1 l of guinea pig com-
plement (Sigma) was added (final concentration, 10%). After another 1-h incu-
bation at 37°C approximately 105 BHK-21 C13 cells in 250 l were added.
Individual wells were scored for cytopathic effect (CPE) following a 48- to 120-h
incubation at 37°C. Each individual virus neutralization test was performed in
triplicate.
In addition a titration experiment was performed as described earlier (14)
using a number of sera from horses that had been inoculated with EAV strain
LP3A or its derivative LP3A. VNAb titers against the EAV strain CVL
Bucyrus and against EAV-GL were determined in parallel.
Immunoprecipitation and gel electrophoresis. Proteins were immunoprecipi-
tated from cell lysates or solubilized virions and analyzed in SDS–15% polyacryl-
amide gels essentially as described previously (71). The samples were incubated
for 15 min at room temperature before being applied to the gel. After electro-
phoresis the gels were processed for fluorography and exposed at 80°C to
Kodak X-ray films as previously reported (71).
Endoglycosidase treatment. Washed immunoprecipitates were treated with
endoglycosidase H (endo H) essentially as described previously (70).
Vaccination and challenge infections of ponies. The EAV-GL inoculum was
prepared by infection of EELs at an MOI of approximately 0.002 with BHK-21
C13-derived virus and incubation for 72 h at 37°C. The tissue culture fluid was
then harvested and freeze-thawed, cell debris was removed by centrifugation,
and aliquots of the supernatant were stored at 70°C. Procedures for EAV
inoculation of ponies have been described previously (14). Two-year-old cas-
trated male Welsh Mountain Ponies (5062, 697b, 7b69, and 07d41), seronegative
for EAV, were used in this study. Ponies 7b69 and 07d41 were stabled in a
contained environment facility and inoculated with 106 TCID50 of EAV-GL by
the intranasopharyngeal route and monitored closely for 28 days. Nasopharyn-
geal swabs, heparinized blood, and serum samples were collected at regular
intervals and analyzed for virus and antibodies as described below. After infec-
tious virus could no longer be detected, the ponies were released from contain-
ment to an isolated barn. Forty-six days after the immunization ponies 7b69 and
07d41 and EAV-seronegative ponies 5062 and 697b were inoculated with 106.1
TCID50 of EAV strain LP3A. All four ponies were clinically inspected twice a
day, and serum, heparinized blood, and nasopharyngeal swabs were collected at
regular intervals until the end of the study. The ponies were released to a third
isolated barn when they were regarded as noninfectious; they were transferred 2
weeks later to an isolated paddock for 4 weeks before they were allowed to have
contact with any other equines.
Virus isolation and serology. Virus isolation from blood and nasopharyngeal
samples and VNAb assays were conducted as previously described (14). The
virus neutralization test was performed with three different EAV strains:
LP3A, CVL Bucyrus, and EAV-GL. Antibody responses to two GL-derived
antigens were analyzed by ELISA in accordance with the procedures described
by Nugent et al. (49) with minor modifications. The antigens chosen were an
ovalbumin-conjugated synthetic peptide representing aa 81 to 106 of GL (GL-
OVA), a region deleted in EAV-GL, and a six-histidine-tagged recombinant
protein expressing the complete GL ectodomain (residues 18 to 122; GL-6His),
both described earlier (49).
RESULTS
Construction of the EAV deletion mutant EAV-GL. To
delete the immunodominant domain of GL and thereby obtain
a potential marker vaccine virus, an EAV infectious cDNA
mutant clone with a deletion of the gene segment specifying
residues 66 to 112 of the GL protein was constructed (Fig. 1).
For this purpose we used the primers 984 (positive polarity)
and 983 (negative polarity), and infectious cDNA clone
pEAN515 served as the template. Primer 984 hybridizes up-
stream of a unique BglII site. Primer 983 hybridizes just up-
FIG. 1. (A) Representation of the 3 part of the EAV genome.
Black box in ORF5, region deleted in the EAV-GL mutant. (B) Hy-
dropathy profile of the EAV GL protein as determined by the method
of Kyte and Doolittle (39) with a seven-residue moving window. Peaks
extending upward indicate hydrophobic domains, and those pointing
downward correspond to hydrophilic regions. Black bar, region de-
leted in the EAV-GL mutant.
8472 CASTILLO-OLIVARES ET AL. J. VIROL.
 o
n
 N
ovem
ber 12, 2015 by University of Queensland Library
http://jvi.asm.org/
D
ow
nloaded from
 
stream of the proposed deletion and contains an extension
corresponding to the oligonucleotide sequence just down-
stream of the deletion, ending after a unique EcoRI site. The
resulting 724-nucleotide PCR fragment was treated with BglII
and EcoRI, and the 638-bp digestion product was cloned into
BglII- and EcoRI-digested pEAN515, yielding pEANGL. The
nucleotide sequence of the insert was verified by sequencing.
In addition, the restriction patterns of pEANGL and its par-
ent plasmid, pEAN515, obtained after digestion with BglII and
EcoRI were compared, which confirmed the expected size re-
duction of the released fragment.
Subsequently, BHK-21 C13 cells were transfected in parallel
with in vitro RNA transcripts derived from pEANGL or from
the parental construct. After electroporation, clear CPE de-
veloped in the cells for both constructs, indicating that EAV-
GL was viable. To investigate the presence and stability of the
mutation, the virus in the culture medium of the electropo-
rated cells was passaged four times in BHK-21 C13 cells, after
which viral RNA was purified from the culture supernatants of
the infected cells and the relevant genome segment was am-
plified by RT-PCR using primers 984 and A2. The resulting
PCR product was cloned into the pGEM-T Easy vector and
sequenced. As shown in Fig. 2 the deletion was still present; no
other mutation could be observed in the PCR product, al-
though point mutations elsewhere in the viral genome can
obviously not be excluded.
Growth properties of the EAV-GL mutant. To investigate
possible effects of the deletion in the GL protein on virus
growth, BHK-21 C13 cells were infected in parallel at similar
high (10) MOIs with the EAV-GL mutant or the parental
virus. Subsequently, aliquots were taken from the culture su-
pernatants at different times, and their infectious titers were
determined. As Fig. 3 shows, the one-step growth curves of the
viruses are very similar. The EAV-GL mutant reproducibly
exhibited a slightly slower onset of extracellular virus produc-
tion, reaching its maximal titer a few hours later than its parent
virus. The maximal titers reached by both viruses were, how-
ever, quite comparable. Consistently, the times of development
of CPE during the infections were also very similar, that of the
mutant again seeming slightly delayed. Similarly, in multistep
growth curves, the mutant virus replicated with slightly slower
kinetics than, but reached titers similar to, those for the wild-
type virus LP3A, used for the challenge infections (data not
shown).
Analysis of the GL protein of EAV-GL. We also studied the
size and the antigenic properties of the GL protein of the
deletion mutant virus. BHK-21 C13 cells were mock infected
or infected with EAV-GL or the parental virus and labeled
with [35S]methionine. Labeled EAV particles present in the
culture supernatants were dissociated by detergents in the
presence of 20 mM NEM and subjected to immunoprecipita-
tion with different antibodies directed against the EAV GL
protein and with an antiserum directed against the M protein
and analyzed by SDS-polyacrylamide gel electrophoresis. As
Fig. 4A reveals, the parental GL protein was precipitated when
each of these antibodies was used. It migrated as the well-
known collection of heterogeneously glycosylated proteins of
about 30 to 38 kDa (21). Also the GL protein behaved het-
erogeneously: after immunoprecipitation with the GL
C se-
rum, which is directed against the protein’s carboxy terminus,
it was seen as a smear of about 28 to 34 kDa, i.e., running
slightly faster than the wild-type protein. In addition, a protein
of 19 kDa was immunoprecipitated; this protein, as discussed
below, probably represents the unglycosylated GL protein. As
expected, the GL protein was not immunoprecipitated by
MAbs 74D(B) and SP25, since these antibodies recognize the
deleted region. Furthermore, like the wild-type GL and M
proteins, the GL protein appears to be disulfide linked to M
because the two proteins were coprecipitated both by the GL
C
antiserum and by the anti-M serum. The apparently lower
ratios of GL levels to M levels in the EAV-GL particles than
in wild-type EAV (Fig. 4A) probably relate to differences in
glycosylation as these differences are not obvious when the
viruses are grown in the presence of DMJ (Fig. 4B). The
identity of the approximately 17-kDa protein which was immu-
noprecipitated from the EAV-GL material by MAb 74D(B)
and which comigrated with the M protein is not clear. The
protein is probably precipitated nonspecifically by MAb
FIG. 2. RT-PCR analysis of the EAV-GL virus. Viral RNA was
purified from supernatants of EAV-GL-infected cells. cDNA synthe-
sis was primed with primer (polarities are in parentheses) A3 (); for
PCR amplification primers 984 () and A2 () were used. The RT-
PCR product was cloned into the pGEM-T Easy vector and se-
quenced. The nucleotide sequence of the relevant part of ORF5 and
the deduced amino acid sequence are shown. Arrowhead, site of de-
letion.
FIG. 3. One-step growth curve for EAV-GL. BHK-21 C13 cell
cultures were infected in parallel at high MOI with the EAV-GL
mutant and the parental virus. Samples were taken from the culture
supernatants at different times p.i., and their infectivity titers were
determined.
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74D(B), since a protein of similar size is also seen in immu-
noprecipitates with different preimmune sera (70, 71). A pro-
tein of 13 kDa represents the EAV nucleocapsid protein,
which is known to be immunoprecipitated nonspecifically (62).
Because their heterogeneous glycosylation precluded a care-
ful size comparison of wild-type and mutant GL proteins, we
repeated the labeling in the presence and absence of DMJ, an
inhibitor of N-linked oligosaccharide processing. Viral parti-
cles in the culture supernatant were solubilized, and proteins
were subjected to immunoprecipitation with the GL
C serum or
its corresponding preserum, after which the precipitates were
treated or mock treated with endo H, which cleaves unproc-
essed oligosaccharides. The electrophoretic analysis (Fig. 4B)
shows that the inhibitor indeed prevented the extensive glyco-
sylation, thereby clearly revealing the size difference between
the wild-type and the mutant GL proteins. In addition, the
deglycosylation by endo H reduced the apparent sizes of both
proteins similarly, indicating that they carried the same num-
ber (i.e., one) of sugar side chains. Finally, the mobility differ-
ence between the deglycosylated proteins is consistent with the
predicted approximately 5-kDa molecular mass difference re-
sulting from the 47-residue deletion.
Neutralization of EAV-GL by antibodies. To study the ef-
fect of the deletion on virus neutralization in vitro, a virus
neutralization assay was performed using the MAbs 93B and
74D(B), the rabbit antipeptide serum SP25, three horse sera
positive for EAV antibodies, and two seronegative horse sera
(Table 2). The MAbs 93B and 74D(B) and SP25 recognize
epitopes in the region deleted from the GL protein ectodo-
main. It turned out that the EAV antibody-positive horse sera
were able to neutralize both EAV-GL and the parental virus.
In contrast, while the two MAbs and SP25 efficiently blocked
infection by the parental virus, they were unable to affect the
infectivity of the EAV-GL mutant virus. The two seronega-
tive horse sera were unreactive to either virus.
In another experiment we comparatively analyzed the
VNAb titers of a panel of sera collected from horses experi-
mentally infected with the virulent EAV strain LP3A or its
single-passage derivative LP3A. These sera were titrated in
parallel against EAV-GL and against EAV strain CVL
Bucyrus, which has a wild-type GL protein. As Table 3 shows,
all sera neutralized the wild-type virus much more efficiently
than the deletion virus EAV-GL, which was neutralized rel-
atively poorly.
Immunization of ponies with EAV-GL. A stock of the mu-
tant virus was prepared in EEL cells. An additional check for
FIG. 4. Immunoprecipitation analysis of EAV-GL. EAV-GL-in-
fected, parental-virus-infected, and mock-infected BHK-21 C13 cells
were labeled with [35S]methionine from 6.5 to 12 h p.i. in the absence
(A) or presence (B) of DMJ. After removal of cell debris by low-speed
centrifugation, the labeled virus present in the cell culture medium was
dissociated in lysis buffer containing 20 mM NEM and subjected to
immunoprecipitation. (A) Samples were immunoprecipitated either
with the MAb 74D(B) or the antipeptide sera GL
C and SP25 (all
against GL) or with the antipeptide serum M (directed against pep-
tide SP06 derived from the M protein). (B) Samples were immuno-
precipitated with GL
C. The immunoprecipitates were treated () or
mock treated () with endo H as indicated. Samples were finally
dissolved in Laemmli sample buffer containing 50 mM dithiothreitol
and analyzed by SDS–15% polyacrylamide gel electrophoresis. Num-
bers on the left refer to positions of the molecular mass markers (in
kilodaltons). Asterisks, positions of the deglycosylated GL polypep-
tides.
TABLE 2. Sensitivity of mutant and parental virus to neutralization
by different antibodies
Serum or MAba
Ability to neutralize:b
EAV-GL Parental virus
MAb 74D(B)  
MAb 93B  
SP25  
Gar (EAV pos.)  
Cyr (EAV pos.)  
Jip (EAV pos.)  
Gie (EAV neg.)  
Ig (EAV neg.)  
a The presence (pos.) or absence (neg.) of antibodies against EAV is indicated
in parentheses.
b , neutralization positive; , neutralization negative.
TABLE 3. Virus neutralization assay results
Pony Virus Sampling day afterinoculation
Log10 VNAb titer for:
CVL Bucyrus EAV-GL
6d2C LP3A 28 2.40 0.75
3566 LP3A 28 2.30 0.75
297e LP3A 14 1.95 	0.60
chnt LP3A 14 2.25 1.05
7378 LP3A 30 2.85 0.75
5d66 LP3A 30 3.40 1.40
027a LP3A 30 2.85 1.05
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the presence of the deletion by RT-PCR as described in Ma-
terials and Methods showed the reduced size of the ORF5-
derived fragment relative to that of the fragment from the
wild-type CVL Bucyrus strain (Fig. 5A). Seronegative ponies
7b69 and 07d41 were inoculated with 106 TCID50 of the mu-
tant virus by the intranasopharyngeal route. The animals were
monitored daily for their general clinical features, while naso-
pharyngeal swabs and blood were collected at regular intervals.
Neither of the two ponies exhibited any apparent signs of
clinical disease. Accordingly, rectal temperatures remained
normal (Table 4). However, cell-associated viremia and naso-
pharyngeal virus excretion were observed in both ponies, dem-
onstrating that infections had been established. Viremia was
first detected on day 4 for pony 7b69 and on day 6 for pony
07d41 and lasted until day 14 in both animals. Thereafter (days
16, 19, and 21; data not shown), virus was no longer detected
in the blood. Virus excretion from the upper respiratory tract
occurred essentially between days 1 and 12; the infectivity was
below 101.5 TCID50/ml except for the sample collected on day
5 from pony 07d41 (101.5 TCID50/ml). RT-PCR analysis of
viral RNA extracted from the virus isolated from a blood
sample collected from pony 7b69 on day 4 postinoculation
confirmed that the recovered virus carried the expected inter-
nal deletion in ORF5 (Fig. 5B). As will be described in more
detail below, both ponies developed significant levels of serum
neutralizing antibodies against the immunizing virus, but de-
velopment of antibodies against EAV strains LP3A and CVL
Bucyrus, which carry wild-type GL proteins, was weak.
Challenge infection of immunized ponies with virulent EAV.
To evaluate the immunity conferred by EAV-GL, the two
immunized ponies together with two EAV-naive controls
(697b and 5062) were inoculated on day 46 after immunization
with 106.1 TCID50 of the virulent EAV strain LP3A by the
intranasopharyngeal route. All animals were again monitored
clinically as well as for their virological and serological re-
sponses.
Both control ponies developed obvious clinical signs. Their
symptoms included pyrexia, depression, anorexia, conjunctivi-
tis, nasal discharge, and ataxia, the well-known sequelae of an
evident EAV infection. In contrast, the preimmunized ponies
07d41 and 7b69 remained asymptomatic during the entire
study period. The rectal temperatures measured during the
first 2 weeks were fully consistent with these observations. As
diagrammed in Fig. 6 high fever developed in the control
ponies during the second day p.i. and remained for almost a
FIG. 5. RT-PCR analysis of ORF5 from EAV-GL inoculated into
(A) and retrieved from (B) ponies. RT-PCR amplification of ORF5
was carried out on tissue culture fluid with primers JV1 and JV2. The
presence of the deletion in ORF5 both for the input virus and the virus
present in the blood of one of the ponies (7b69) was checked at day 4
after inoculation with EAV-GL. Lane 1, EAV-GL inoculum virus
prepared in EEL cells; lanes 2 and 3, wild-type EAV strain CVL
Bucyrus grown in RK13 cells; lane 4, uninfected RK13 tissue culture
fluid; lane 5, virus recovered in RK13 cells from an EAV-GL-infected
pony (7b69); lane 6, challenge virus (LP3A) prepared in EEL cells.
On the left the positions and sizes of marker DNA fragments are
indicated.
FIG. 6. Pyrexia (top) and nasal virus excretion (bottom) deter-
mined over a 14-day period for prevaccinated (7b69 and 07d41) and
control ponies (5062 and 697b) following intranasopharyngeal chal-
lenge with EAV strain LP3A.
TABLE 4. Monitoring of pyrexia, viremia, and nasal virus excretion
after intranasal inoculation of ponies with EAV-GL
Day
Pony 07d41 Pony 7b69
Virus isolationa
from: Temp (°C)
Virus isolation
from: Temp (°C)
Swab Blood Swab Blood
0 37.8 37.6
1  37.9 37.9
2   37.4   37.4
3  37.8  37.8
4  37.7   37.9
5  38.1  38.1
6   37.8   38.0
7  37.9  38.1
8  38.0  37.7
9
10   38.0   38.1
11
12   37.8   38.1
13
14    
a , virus isolation positive; , virus isolation negative.
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week, while no obvious elevation in body temperature was
observed in the vaccinated animals. Viremia was obvious in the
control ponies from day 2 until day 21 p.i., whereas virus was
detected only on day 8 in blood from both vaccinated ponies
(data not shown). Virus was excreted from the upper respira-
tory tracts of the control animals during the first 10 to 12 days,
peaking around day 5 p.i.; viral infectivities in the nasal swab
extracts were very high (103 TCID50/ml) between days 2 and
9 (697b) and 2 and 7 (5062), reaching maximum levels exceed-
ing 105 TCID50/ml. In contrast, for the immunized ponies,
7b69 and 07d41, virus was isolated on only one and two occa-
sions, respectively, and the infectivity remained below 101.5
TCID50/ml.
Neutralizing-antibody responses to vaccination and chal-
lenge infection. The sera collected throughout the experiment
were used to determine the development of virus-neutralizing
activity in each individual animal. To evaluate the effect of the
lack of the immunodominant region of GL in the vaccine virus,
we analyzed the VNAb titers not only against EAV-GL but
also against EAV strains LP3A and CVL Bucyrus, which
carry wild-type GL proteins. The results of the assays are com-
piled in Fig. 7. Following immunization, ponies 7b69 and 07d41
developed a weak VNAb response against the CVL Bucyrus
and LP3A strains. By day 14 p.i., neutralizing antibodies
against only the LP3A strain for a single pony were detect-
able. The VNAb titers increased slightly until the day of the
challenge on day 46, when low log titers (less than 1.0) for both
EAV wild-type strains were detectable in both ponies. In con-
trast, the response against EAV-GL was much stronger,
reaching log titers of 1.35 and 0.8 already by day 14 p.i. and 2.2
and 2.8 on day 21 for ponies 7b69 and 07d41, respectively. At
the time of challenge, VNAb titers for both immunized ponies
against EAV-GL were at least 10 times higher than those
against the wild-type strains.
After the challenge both immunized ponies responded with
a further increase in neutralizing antibodies against all three
viruses, with titers against EAV-GL being generally higher.
The control ponies showed a typical VNAb response after
EAV infection against both wild-type viruses, with titers de-
tectable by day 6 and increasing rapidly to reach high log values
of around 3 by day 14. In contrast the titers against the EAV-
GL virus were very low.
Evaluation of GL-specific antibody responses. The availabil-
ity of GL-based ELISAs that Nugent et al. established recently
(49) allowed us to analyze the antibody responses directed
against the entire GL ectodomain (residues 18 to 122) and
against a part (residues 81 to 106) of the domain deleted in
EAV-GL (residues 66 to 112). The former test uses as an
antigen a His-tagged bacterial expression product (GL-6His),
while in the latter assay an ovalbumin-coupled synthetic pep-
tide (GL-OVA) is applied to the ELISA plates. Selected serum
samples from the four ponies were analyzed in parallel with a
positive-control serum taken from a pony that had been im-
munized twice with the GL-6His protein (pony p6, 2 weeks
after vaccination with the GL-6His antigen [14]). The results,
expressed as the percentages of the ELISA reactivities with
respect to the control, are compiled in Fig. 8. As expected, the
vaccination of ponies 7b69 and 07d4 with EAV-GL did not
induce a detectable antibody response against the deleted GL
domain. Reactivity against GL-OVA became measurable only
after the challenge infection with wild-type EAV, particularly
in the nonvaccinated animals. However, induction of anti-GL-
OVA responses was higher for control ponies (60 to 80%
reactivity by day 60) than for EAV-GL-vaccinated ponies
(	10 to 30% reactivity by day 60). In contrast, both vaccinated
ponies developed an antibody response against GL-6His, which
was subsequently boosted after challenge, becoming at least
threefold higher than that those against GL-OVA. In the two
control ponies, however, the challenge infection induced anti-
body responses against the two antigens that, in contrast to
those for the preimmunized ponies, were at similar levels for
both antigens.
FIG. 7. Virus-neutralizing antibody responses in serum of ponies
7b69, 07d41, 5062, and 697b against EAV-GL (), LP3A (F), and
CVL Bucyrus (‚) after intranasopharyngeal vaccination (ponies 7b69
and 07d41) with EAV-GL (day 0) and intranasopharyngeal challenge
infection with EAV LP3A (day 46; arrows).
FIG. 8. GL protein-specific antibody responses of ponies 7b69,
07d41, 5062, and 697b after intranasopharyngeal immunization (po-
nies 7b69 and 07d41) with EAV-GL (day 0) and intranasopharyngeal
challenge infection with EAV LP3A (day 46; arrows) measured by
ELISA for antigens GL-6His (GL residues 18 to 122) and GL-OVA
(GL residues 81 to 106). Reactivities of sera are expressed with respect
to that for a positive-control serum sample obtained from pony p6 2
weeks after vaccination with GL-6His antigen (14).
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DISCUSSION
It has been generally assumed that protection against EAV
infection is mediated via high levels of virus-neutralizing anti-
body. In this study we prepared, in the controlled background
of a nonvirulent virus, a mutant EAV lacking the domain
against which the vast majority of virus-neutralizing antibodies
are directed. The virus, which replicated with slightly delayed
kinetics compared to the parent in tissue culture, caused an
asymptomatic infection in ponies, during which it induced an
antibody response which in vitro neutralized the mutant virus
efficiently but neutralized wild-type EAV strains only poorly.
Nevertheless, the immunity induced via mutant virus infection
protected the animals effectively against subsequent challenge
infection with virulent EAV. Protection in the absence of sig-
nificant neutralizing antibodies against the challenge virus sug-
gests that an alternative immune effector mechanism was re-
sponsible. Because the mutant virus, as expected, did not
induce an antibody response against a peptide antigen derived
from the deleted region—on the basis of which a sensitive
EAV ELISA was recently established—our work provides a
potential candidate EAV marker vaccine.
Arteriviruses do not carry the conspicuous spike structures
that other nidoviruses exhibit on their surfaces. Rather, elec-
tron-microscopic studies of EAV showed only tiny, ringlike
projections on the otherwise smooth envelopes of viral parti-
cles (38, 41). Analyses of the protein structure of virions led to
the concept that these projections are formed by the disulfide-
linked ectodomains of the main envelope proteins GL and M
(23). Actually, as the M protein ectodomain contributes only
some 15 to 18 exposed residues, the surface structures are
supposedly composed mainly of the GL protein, including the
huge oligosaccharide side chain attached to it (21). Because
EAV-neutralizing antibodies are directed against the GL
ectodomain, it was speculated that the surface projections de-
termine viral tropism, via involvement in receptor recognition.
It was therefore quite surprising that the virus appeared to
tolerate dramatic changes in its GL protein without any notice-
able changes in its in vitro cell tropism. Thus, MAb escape
mutants lacking up to 47 aa of the 97-residue ectodomain were
obtained (8), while replacement of even the complete ectodo-
main by that of the GL protein of lactate dehydrogenase-
elevating virus or porcine reproductive and respiratory syn-
drome virus generated viruses that, though significantly
attenuated in their growth, maintained their ability to infect
BHK-21 and RK-13 cells (24). In our studies we observed that
the deletion mutant created was still able to infect BHK cells
in vitro and equine cells in vivo, although the virus seemed to
have replicated at a slower rate than wild-type EAV. Alto-
gether these data indicate that the GL protein is therefore
unlikely to be critical for receptor targeting although it may
still serve some other function in viral entry.
An essential requirement for any live virus vaccine is that it
be avirulent, inducing no or at most very mild disease mani-
festations. EAV-GL was likely to fulfill this requirement be-
cause it was derived from a full-size infectious cDNA clone
previously shown to produce nonvirulent virus (10). Intranasal
inoculation of two stallions each with 2  106.25 TCID50 of this
virus caused a transient infection without clinical symptoms
apart from very mild pyrexia. However, the effect of deleting
the immunodominant region of EAV could not a priori be
predicted, since it might either have resulted in attenuation or
have increased virulence, as a result of a reduced induction of
neutralizing antibody responses.
The present study allowed us to evaluate the immunity
against EAV infection provided by exposure to the deletion
mutant virus. Both ponies inoculated with EAV-GL mounted
an immune response to EAV as evidenced by the detection of
antibodies in serum against the whole GL ectodomain and by
the demonstration of VNAb against wild-type EAV. We ob-
served complete clinical protection against the virulent
LP3A virus, accompanied by only occasional isolation of
challenge virus from nasal swabs and blood in the vaccinated
ponies. This level of protection was unexpected in the light of
the relatively low log VNAb titers (1.2 and 0.8) against LP3A
at the time of challenge. These VNAb were stimulated after
EAV-GL infection and boosted after challenge although the
GL ectodomain was partially deleted from the immunizing
virus. Consequently, these antibodies must either recognize
epitopes in the modified GL polypeptide (antigenic sites A and
B as identified by Balasuriya et al. [8] are still present in the
deletion mutant virus) or be directed to yet-unidentified neu-
tralizing epitopes lying outside the GL protein.
However, it seems unlikely that VNAb alone can have pro-
vided the levels of protection observed. Previous studies (14)
showed that ponies vaccinated with a recombinant protein
comprising the entire GL ectodomain and presenting log titers
of around 1.0 at the time of challenge were only partially
protected, although these ponies showed a significant anam-
nestic response after infection. More likely, the intranasal ad-
ministration of a replicative immunogen stimulated a wide
range of immune effector mechanisms, not dependent on the
deleted region of the GL protein. Thus, strong VNAb re-
sponses directed against epitopes outside the GL (aa 66 to 112)
region may have been elicited efficiently, particularly at the
natural port of virus entry in the nasal mucosa. Alternatively,
cell-mediated immunity may have contributed to the protec-
tion against challenge infection. Antibody-dependent cell-me-
diated cytotoxicity and cytotoxic T lymphocytes (CTL) in the
horse have been described (1, 50). Recently, methods for the
detection of EAV-specific cytotoxic responses have been de-
veloped and the induction of CD8 CTL responses following
wild-type EAV infection has been demonstrated (Castillo-Oli-
vares et al., unpublished data). These and other methods
should enable us to characterize the immune effector mecha-
nisms that are stimulated after immunization with EAV-GL
and to evaluate the relative importance of antibody- versus
cell-mediated mechanisms.
Both live-attenuated and killed-virus vaccines for EAV are
presently commercially available. The live vaccine is a modified
virus that has been attenuated for horses by multiple serial
transfers in equine and rabbit cell cultures (42, 44, 59). It has
been shown to be safe and protective for stallions and non-
pregnant mares. Vaccination of foals under 6 weeks of age and
of pregnant mares in the final 2 months of gestation is contra-
indicated. The killed-virus vaccine is an inactivated, adjuvanted
product prepared from virus grown in equine cell culture that
can be used in nonbreeding and breeding horses though its use
in pregnant mares is not recommended (26, 42, 43). The effi-
cacy of live vaccines is generally higher since they stimulate a
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wider range of immune effector responses and the immunity
lasts longer than that produced by inactivated-virus vaccines.
EAV-GL is therefore a very attractive vaccine candidate for
the future as it combines all the desired features of a live-
attenuated virus with the additional ability to discriminate vac-
cinated from infected animals.
Marker vaccines are characterized by the absence of one or
more proteins, or parts thereof, of the pathogen. Thus, anti-
bodies against the deleted polypeptide(s) allow vaccinated an-
imals to be differentiated from infected ones. These vaccines
have become attractive or mandatory in programs aimed at
controlling or eradicating virus infections in food as well as in
companion animals (2–4, 65). Herpesvirus (glycoprotein gE-
deleted pseudorabies virus and bovine herpesvirus) marker
vaccines were among the first to be developed and used in the
field (66), followed later by various genetically modified RNA
viruses such as classical swine fever virus (64, 69) and New-
castle disease virus (47, 51). Marker vaccines can be based on
live and inactivated viruses as well as on viral subunits, but they
also include DNA and vector vaccines. The essential feature is
the availability of a test that can identify infected animals
irrespective of their vaccination status.
Despite the availability and efficacy of current live and in-
activated EAV vaccines, their use suffers from the drawback of
not permitting discrimination of vaccinated from naturally in-
fected animals. Consequently their use is restricted in order to
avoid confounding disease surveillance and prevention pro-
grams. Equine viral arteritis is a contagious disease that can be
silently introduced by asymptomatic carrier stallions and easily
spread in naive equine populations, as has been documented
(72). Spread of the virus is additionally facilitated by specific
features of the horse industry, which is characterized by active
international trade and traffic. Moreover, horses are frequently
used in various branches of equestrian sport, which necessi-
tates close contacts between animals, often from all points of
the compass, thereby increasing the risk of exposure. All these
conditions call for a marker vaccine. This need is also realized
by the legislative authorities, for which the discrimination be-
tween vaccination and infection is becoming a ruling issue. In
view of its performance and of the availability of a sensitive
discriminating ELISA, EAV-GL has the potential to be a
live-attenuated marker vaccine.
Immunization of ponies with EAV-GL went without no-
ticeable clinical symptoms. Subsequent inoculation with viru-
lent EAV showed that the vaccination prevented disease while
strongly reducing infection by the challenge virus: infectivity
was briefly observed in nasal secretions and blood at low but
detectable levels. Promising as these observations are, several
features of the candidate vaccine yet need to be established. It
will, for instance, be important to determine the duration of
the immunity provided. Moreover, it will be of interest to know
whether the vaccine virus can cause a persistent infection in
stallions. Furthermore, it will be important to evaluate the
performance of the virus in pregnant mares in order to find out
whether it is sufficiently attenuated to not be abortigenic. The
results of these and other studies will set the conditions under
which the vaccine may eventually be deployed.
ACKNOWLEDGMENTS
Roeland Wieringa and Javier Castillo-Olivares contributed equally
to this work.
We are very grateful to Martin Raamsman for technical assistance
for the preparation of the antiserum directed against the carboxy
terminus of the EAV GL protein. We thank Eric Snijder for making
available the full-length EAV cDNA clone pEAN515.
Part of this work was supported by the BBSRC (United Kingdom).
Nick J. Davis-Poynter was supported by a Tetra Laval Senior Fellow-
ship.
REFERENCES
1. Allen, G., M. Yeargan, L. R. Costa, and R. Cross. 1995. Major histocompat-
ibility complex class I-restricted cytotoxic T-lymphocyte responses in horses
infected with equine herpesvirus 1. J. Virol. 69:606–612.
2. Babiuk, L., J. Lewis, S. Suradhat, M. Baca-Estrada, M. Foldvari, and S.
Babiuk. 1999. Polynucleotide vaccines: potential for inducing immunity in
animals. J. Biotechnol. 73:131–140.
3. Babiuk, L. A. 1999. Broadening the approaches to developing more effective
vaccines. Vaccine 17:1587–1595.
4. Babiuk, L. A., S. L. Babiuk, and M. E. Baca-Estrada. 2002. Novel vaccine
strategies. Adv. Virus Res. 58:29–80.
5. Balasuriya, U. B., H. W. Heidner, N. L. Davis, H. M. Wagner, P. J. Hullinger,
J. F. Hedges, J. C. Williams, R. E. Johnston, W. W. David, I. K. Liu, and M. L.
James. 2002. Alphavirus replicon particles expressing the two major envelope
proteins of equine arteritis virus induce high level protection against challenge
with virulent virus in vaccinated horses. Vaccine 20:1609–1617.
6. Balasuriya, U. B., H. W. Heidner, J. F. Hedges, J. C. Williams, N. L. Davis, R. E.
Johnston, and N. J. MacLachlan. 2000. Expression of the two major envelope
proteins of equine arteritis virus as a heterodimer is necessary for induction of
neutralizing antibodies in mice immunized with recombinant Venezuelan
equine encephalitis virus replicon particles. J. Virol. 74:10623–10630.
7. Balasuriya, U. B., N. J. MacLachlan, A. A. F. de Vries, P. V. Rossitto, and
P. J. M. Rottier. 1995. Identification of a neutralization site in the major
envelope glycoprotein (GL) of equine arteritis virus. Virology 207:518–527.
8. Balasuriya, U. B., J. F. Patton, P. V. Rossitto, P. J. Timoney, W. H. McCol-
lum, and N. J. MacLachlan. 1997. Neutralization determinants of laboratory
strains and field isolates of equine arteritis virus: identification of four neu-
tralization sites in the amino-terminal ectodomain of the GL envelope gly-
coprotein. Virology 232:114–128.
9. Balasuriya, U. B., P. V. Rossitto, C. D. DeMaula, and N. J. MacLachlan.
1993. A 29K envelope glycoprotein of equine arteritis virus expresses neu-
tralization determinants recognized by murine monoclonal antibodies.
J. Gen. Virol. 74:2525–2529.
10. Balasuriya, U. B., E. J. Snijder, L. C. van Dinten, H. W. Heidner, W. D.
Wilson, J. F. Hedges, P. J. Hullinger, and N. J. MacLachlan. 1999. Equine
arteritis virus derived from an infectious cDNA clone is attenuated and
genetically stable in infected stallions. Virology 260:201–208.
11. Balasuriya, U. B., P. J. Timoney, W. H. McCollum, and N. J. MacLachlan.
1995. Phylogenetic analysis of open reading frame 5 of field isolates of
equine arteritis virus and identification of conserved and nonconserved re-
gions in the GL envelope glycoprotein. Virology 214:690–697.
12. Bryans, J. T., E. R. Doll, M. E. W. Crowe, and W. H. McCollum. 1957. The
blood picture and thermal reaction in experimental viral arteritis of horses.
Cornell Vet. 47:42–52.
13. Bryans, J. T., E. R. Doll, J. C. Wilson, and W. H. McCollum. 1966. Immu-
nization for equine influenza. J. Am. Vet. Med. Assoc. 148:413–417.
14. Castillo-Olivares, J., A. A. F. de Vries, M. J. B. Raamsman, P. J. M. Rottier,
K. Lakhani, D. Westcott, J. P. Tearle, J. L. N. Wood, J. A. Mumford, D.
Hannant, and N. J. Davis-Poynter. 2001. Evaluation of a prototype sub-unit
vaccine against equine arteritis virus comprising the entire ectodomain of the
virus large envelope glycoprotein (GL): induction of virus-neutralizing anti-
body and assessment of protection in ponies. J. Gen. Virol. 82:2425–2435.
15. Chirnside, E. D., A. A. F. de Vries, J. A. Mumford, and P. J. M. Rottier. 1995.
Equine arteritis virus-neutralizing antibody in the horse is induced by a deter-
minant on the large envelope glycoprotein GL. J. Gen. Virol. 76:1989–1998.
16. Collins, J. K., S. Kari, S. L. Ralston, D. G. Bennet, J. L. Traub Dargatz, and
A. O. McKinnon. 1987. Equine viral arteritis in a veterinary teaching hospi-
tal. Prev. Vet. Med. 4:389–397.
17. Dea, S., C. A. Gagnon, H. Mardassi, B. Pirzadeh, and D. Rogan. 2000.
Current knowledge on the structural proteins of porcine reproductive and
respiratory syndrome (PRRS) virus: comparison of the North American and
European isolates. Arch. Virol. 145:659–688.
18. Deregt, D., A. A. F. de Vries, M. J. B. Raamsman, L. D. Elmgren, and P. J. M.
Rottier. 1994. Monoclonal antibodies to equine arteritis virus proteins iden-
tify the GL protein as a target for virus neutralization. J. Gen. Virol. 75:
2439–2444.
19. de Vries, A. A. F. 1994. The molecular biology of equine arteritis virus. Ph.D.
thesis. Utrecht University, Utrecht, The Netherlands.
20. de Vries, A. A. F., E. D. Chirnside, P. J. Bredenbeek, L. A. Gravestein, M. C.
8478 CASTILLO-OLIVARES ET AL. J. VIROL.
 o
n
 N
ovem
ber 12, 2015 by University of Queensland Library
http://jvi.asm.org/
D
ow
nloaded from
 
Horzinek, and W. J. M. Spaan. 1990. All subgenomic mRNAs of equine
arteritis virus contain a common leader sequence. Nucleic Acids Res. 18:
3241–3247.
21. de Vries, A. A. F., E. D. Chirnside, M. C. Horzinek, and P. J. M. Rottier.
1992. Structural proteins of equine arteritis virus. J. Virol. 66:6294–6303.
22. de Vries, A. A. F., A. L. Glaser, M. J. B. Raamsman, C. A. M. de Haan, S.
Sarnataro, G. J. Godeke, and P. J. M. Rottier. 2000. Genetic manipulation
of equine arteritis virus using full-length cDNA clones: separation of over-
lapping genes and expression of a foreign epitope. Virology 270:84–97.
23. de Vries, A. A. F., S. M. Post, M. J. B. Raamsman, M. C. Horzinek, and
P. J. M. Rottier. 1995. The two major envelope proteins of equine arteritis
virus associate into disulfide-linked heterodimers. J. Virol. 69:4668–4674.
24. Dobbe, J. C., Y. van der Meer, W. J. M. Spaan, and E. J. Snijder. 2001.
Construction of chimeric arteriviruses reveals that the ectodomain of the
major glycoprotein is not the main determinant of equine arteritis virus
tropism in cell culture. Virology 288:283–294.
25. Doll, E. R., J. T. Bryans, W. H. McCollum, and M. E. W. Crowe. 1957.
Isolation of a filterable agent causing arteritis of horses and abortion by
mares. Its differentiation from the equine abortion (influenza) virus. Cornell
Vet. 47:3–41.
26. Doll, E. R., J. T. Bryans, J. C. Wilson, and W. H. McCollum. 1968. Immu-
nization against equine viral arteritis using modified live virus propagated in
cell cultures of rabbit kidney. Cornell Vet. 48:497–524.
27. Doll, E. R., R. E. Knappenberg, and J. T. Bryans. 1957. An outbreak of
abortion caused by the equine arteritis virus. Cornell Vet. 47:69–75.
28. Edwards, S., J. Castillo-Olivares, A. Cullinane, J. Lable, J. Lenihan, J. A.
Mumford, D. J. Paton, J. E. Pearson, R. Sinclair, D. G. F. Westcott, J. L. N.
Wood, S. Zientara, and M. Nelly. 1998. International harmonization of
laboratory diagnostic tests for equine viral arteritis, p. 359–362. In U. Wern-
ery, J. F. Wade, J. A. Mumford, and O.-R. Kaaden (ed.), Proceedings of the
8th International Conference on Equine Infectious Diseases. R&W Publi-
cations, Newmarket, United Kingdom.
29. Estes, P. C., and N. F. Cheville. 1970. The ultrastructure of vascular lesions
in equine viral arteritis. Am. J. Pathol. 58:235–253.
30. Fukunaga, Y., H. Imagawa, E. Tabuchi, and Y. Akiyama. 1981. Clinical and
virological findings on experimental equine viral arteritis in horses. Bull.
Equine Res. Inst. 18:110–118.
31. Fukunaga, Y., T. Matsumura, T. Sugiura, R. Wada, H. Imagawa, T. Kane-
maru, and M. Kamada. 1994. Use of the serum neutralisation test for equine
viral arteritis with different virus strains. Vet. Rec. 134:574–576.
32. Fukunaga, Y., R. Wada, H. Imagawa, and T. Kanemaru. 1997. Venereal
infection of mares by equine arteritis virus and use of killed vaccine against
the infection. J. Comp. Pathol. 117:201–208.
33. Fukunaga, Y., R. Wada, T. Kanemaru, H. Imagawa, M. Kamada, and T.
Samejima. 1996. Immune potency of lyophilized, killed vaccine for equine
viral arteritis and its protection against abortion in pregnant mares. J. Equine
Vet. Sci. 16:217–221.
34. Fukunaga, Y., R. Wada, T. Matsumura, T. Sugiura, and H. Imagawa. 1990.
Induction of immune response and protection from equine viral arteritis
(EVA) by formalin inactivated-virus vaccine for EVA in horses. Zentralbl.
Vetmed. Reihe B 37:135–141.
35. Glaser, A. L., A. A. F. de Vries, and E. J. Dubovi. 1995. Comparison of equine
arteritis virus isolates using neutralizing monoclonal antibodies and identi-
fication of sequence changes in GL associated with neutralization resistance.
J. Gen. Virol. 76:2223–2233.
36. Glaser, A. L., A. A. F. de Vries, P. J. M. Rottier, M. C. Horzinek, and B.
Colenbrander. 1996. Equine arteritis virus: a review of clinical features and
management aspects. Vet. Q. 18:95–99.
37. Hardy, E., H. Santana, A. Sosa, L. Hernandez, C. Fernandez-Patron, and L.
Castellanos-Serra. 1996. Recovery of biologically active proteins detected
with imidazole-sodium dodecyl sulfate-zinc (reverse stain) on sodium dode-
cyl sulfate gels. Anal. Biochem. 240:150–152.
38. Hyllseth, B. 1973. Structural proteins of equine arteritis virus. Arch. Ge-
samte Virusforsch. 40:177–188.
39. Kyte, J., and R. F. Doolittle. 1982. A simple method for displaying the
hydropathic character of a protein. J. Mol. Biol. 157:105–132.
40. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of
the head of bacteriophage T4. Nature 227:680–685.
41. Magnusson, P., B. Hyllseth, and H. Marusyk. 1970. Morphological studies
on equine arteritis virus. Arch. Gesamte Virusforsch. 30:105–112.
42. McCollum, W. H. 1969. Development of a modified virus strain and vaccine
for equine viral arteritis. J. Am. Vet. Med. Assoc. 155:318–322.
43. McCollum, W. H. 1970. Vaccination for equine arteritis virus, p. 143–151. In
J. T. Bryans and H. Gerber (ed.), Proceeding of the 2nd International
Conference on Equine Infectious Diseases. S. Karger, Basel, Switzerland.
44. McCollum, W. H. 1986. Responses of horses vaccinated with avirulent mod-
ified-live equine arteritis virus propagated in the E. Derm (NBL-6) cell line
to nasal inoculation with virulent virus. Am. J. Vet. Res. 47:1931–1934.
45. McCollum, W. H. 2002. Studies of passive immunity in foals to equine viral
arteritis. Vet. Microbiol. 1:45–54.
46. McCollum, W. H., and J. T. Bryans. 1973. Serological identification of
infection by equine arteritis virus in horses of several countries, p. 256–263.
In J. T. Bryans and H. Gerber (ed.), Proceedings of the 3rd International
Conference on Equine Infectious Diseases. S. Karger, Basel, Switzerland.
47. Mebatsion, T., M. J. Koolen, L. T. de Vaan, N. de Haas, M. Braber, A.
Romer-Oberdorfer, P. van den Elzen, and P. van der Marel. 2002. Newcastle
disease virus (NDV) marker vaccine: an immunodominant epitope on the
nucleoprotein gene of NDV can be deleted or replaced by a foreign epitope.
J. Virol. 76:10138–10146.
48. Neu, S. M., P. J. Timoney, and S. R. Lowry. 1992. Changes in semen quality
following experimental equine arteritis virus infection in the stallion. Ther-
iogenology 37:407–431.
49. Nugent, J., R. Sinclair, A. A. F. de Vries, R. Y. Eberhardt, J. Castillo-
Olivares, N. J. Davis-Poynter, P. J. M. Rottier, and J. A. Mumford. 2000.
Development and evaluation of ELISA procedures to detect antibodies
against the major envelope protein (G(L)) of equine arteritis virus. J. Virol.
Methods 90:167–183.
50. O’Neill, T., J. H. Kydd, G. P. Allen, E. Wattrang, J. A. Mumford, and D.
Hannant. 1999. Determination of equid herpesvirus 1-specific, CD8, cyto-
toxic T lymphocyte precursor frequencies in ponies. Vet. Immunol. Immu-
nopathol. 70:43–54.
51. Peeters, B. P., O. S. de Leeuw, I. Verstegen, G. Koch, and A. L. Gielkens.
2001. Generation of a recombinant chimeric Newcastle disease virus vaccine
that allows serological differentiation between vaccinated and infected ani-
mals. Vaccine 19:1616–1627.
52. Plagemann, P. G. W., and V. Moennig. 1992. Lactate dehydrogenase-elevat-
ing virus, equine arteritis virus, and simian hemorrhagic fever virus: a new
group of positive-strand RNA viruses. Adv. Virus Res. 41:99–192.
53. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a
laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold
Spring Harbor, N.Y.
54. Snijder, E. J., and J. J. M. Meulenberg. 1998. The molecular biology of
arteriviruses. J. Gen. Virol. 79:961–979.
55. Snijder, E. J., H. van Tol, K. W. Pedersen, M. J. B. Raamsman, and A. A. F.
de Vries. 1999. Identification of a novel structural protein of arteriviruses.
J. Virol. 73:6335–6345.
56. Stadejek, T., H. Bjorklund, C. R. Bascunana, I. M. Ciabatti, M. T. Scicluna,
D. Amaddeo, W. H. McCollum, G. L. Autorino, P. J. Timoney, D. J. Paton,
B. Klingeborn, and S. Belak. 1999. Genetic diversity of equine arteritis virus.
J. Gen. Virol. 80:691–699.
57. St. Laurent, G., N. Lepage, S. Carman, and D. Archambault. 1997. Genetic
and amino acid analysis of the GL protein of Canadian, American and
European equine arteritis virus isolates. Can. J. Vet. Res. 61:72–76.
58. Timoney, P. J., and W. H. McCollum. 1987. Equine viral arteritis. Can. Vet.
J. 28:693–695.
59. Timoney, P. J., and W. H. McCollum. 1988. Equine viral arteritis: epidemi-
ology and control. J. Equine Vet. Sci. 8:54–59.
60. Timoney, P. J., and W. H. McCollum. 1993. Equine viral arteritis. Vet. Clin.
N. Am. Equine Pract. 9:295–309.
61. Vaala, W. E., A. N. Hamir, E. J. Dubovi, P. J. Timoney, and B. Ruiz. 1992.
Fatal, congenitally acquired infection with equine arteritis virus in a neonatal
Thoroughbred. Equine Vet. J. 24:155–158.
62. van Berlo, M. F., J. J. W. Zeegers, M. C. Horzinek, and B. A. M. van der
Zeijst. 1983. Antigenic comparison of equine arteritis virus (EAV) and
lactic dehydrogenase virus (LDV); binding of staphylococcal protein A to
the nucleocapsid protein of EAV. Zentralbl. Vetmed. Reihe B 30:297–
304.
63. van Dinten, L. C., J. A. den Boon, A. L. M. Wassenaar, W. J. M. Spaan, and
E. J. Snijder. 1997. An infectious arterivirus cDNA clone: identification of a
replicase point mutation that abolishes discontinuous mRNA transcription.
Proc. Natl. Acad. Sci. USA 94:991–996.
64. van Gennip, H. G., A. Bouma, P. A. van Rijn, M. N. Widjojoatmodjo, and
R. J. Moormann. 2002. Experimental non-transmissible marker vaccines for
classical swine fever (CSF) by trans-complementation of E(rns) or E2 of
CSFV. Vaccine 20:1544–1556.
65. van Oirschot, J. T. 2001. Present and future of veterinary viral vaccinology:
a review. Vet. Q. 23:100–108.
66. van Oirschot, J. T., M. J. Kaashoek, F. A. Rijsewijk, and J. A. Stegeman.
1996. The use of marker vaccines in eradication of herpesviruses. J. Biotech-
nol. 44:75–81.
67. Weiland, E., S. Bolz, F. Weiland, W. Herbst, M. J. B. Raamsman, P. J. M.
Rottier, and A. A. F. de Vries. 2000. Monoclonal antibodies directed against
conserved epitopes on the nucleocapsid protein and the major envelope
glycoprotein of equine arteritis virus. J. Clin. Microbiol. 38:2065–2075.
68. Westcott, D., M. H. Lucas, and D. J. Paton. 1995. Equine arteritis virus:
antigenic analysis of strain variation, p. 479–483. In M. Schwyzer, M. Ack-
ermann, G. Bertoni, R. Kocherhaus, K. McCullough, M. Engels, R. Wittek,
and R. Zanoni (ed.), Immunobiology of viral infections. Proceedings of the
3rd Congress of the European Society for Veterinary Virology. Fondation
Marcel Merieux, Lyon, France.
69. Widjojoatmodjo, M. N., H. G. van Gennip, A. Bouma, P. A. van Rijn, and
R. J. Moormann. 2000. Classical swine fever virus E(rns) deletion mutants:
trans-complementation and potential use as nontransmissible, modified, live-
attenuated marker vaccines. J. Virol. 74:2973–2980.
VOL. 77, 2003 EQUINE ARTERITIS VIRUS MARKER VACCINE 8479
 o
n
 N
ovem
ber 12, 2015 by University of Queensland Library
http://jvi.asm.org/
D
ow
nloaded from
 
70. Wieringa, R., A. A. F. de Vries, and P. J. M. Rottier. 2003. Formation of
disulfide-linked complexes between the three minor envelope glycoproteins
(GP2b, GP3, and GP4) of equine arteritis virus. J. Virol. 77:6216–6226.
71. Wieringa, R., A. A. F. de Vries, M. J. B. Raamsman, and P. J. M. Rottier.
2002. Characterization of two new structural glycoproteins, GP3 and GP4, of
equine arteritis virus. J. Virol. 76:10829–10840.
72. Wood, J. L., E. D. Chirnside, J. A. Mumford, and A. J. Higgins. 1995. First
recorded outbreak of equine viral arteritis in the United Kingdom. Vet. Rec.
136:381–385.
73. Yamaguchi, S., T. Kanno, H. Akashi, and T. Kondo. 1997. Identification of
two neutralization sites in GL protein of equine arteritis virus by means of
monoclonal antibodies. J. Equine Sci. 8:7–11.
74. Zeegers, J. J. W., B. A. M. van der Zeijst, and M. C. Horzinek. 1976. The
structural proteins of equine arteritis virus. Virology 73:200–205.
8480 CASTILLO-OLIVARES ET AL. J. VIROL.
 o
n
 N
ovem
ber 12, 2015 by University of Queensland Library
http://jvi.asm.org/
D
ow
nloaded from
 
